Page 1 | Search Results | Cancer Research | American Association for Cancer Research

1-20 of 72

Sort by

Sort Order Select

Journal Articles

Correction: SCF^FBXW7/GSK3β-Mediated GFI1 Degradation Suppresses Proliferation of Gastric Cancer Cells

Xiaoling Kuai, Long Li, Ran Chen, Kangjunjie Wang, Min Chen, Binghau Cui, Yuxue Zhang, Junqiang Li, Hongwen Zhu, Hu Zhou, Jianfei Huang, Jun Qin, Zhiwei Wang, Wenyi Wei, Daming Gao

Cancer Res (2025) 85 (9): 1739.

https://doi.org/10.1158/0008-5472.CAN-25-1051

Published: 02 May 2025

View articletitled, Correction: SCFFBXW7/GSK3β-Mediated GFI1 Degradation Suppresses Proliferation of Gastric Cancer Cells

Journal Articles

Abstract 7323: LBL-043, a novel LILRB4xCD3 T cell engager, for the treatment of relapsed/refractory multiple myeloma

Yujia Dang, Xiao Huang, Yurong Qin, Xiaoya Liu, Min Chen, Duqing Jiang, Guojin Wu, Mi Ye, Jianming Sun, Hong Ling, Shoupeng Lai, Xiaoqiang Kang, Jordan Zhu

Cancer Res (2025) 85 (8_Supplement_1): 7323.

https://doi.org/10.1158/1538-7445.AM2025-7323

Published: 21 April 2025

View articletitled, Abstract 7323: LBL-043, a novel LILRB4xCD3 T cell engager, for the treatment of relapsed/refractory multiple myeloma

Journal Articles

Abstract 4624: Analysis of the characteristics of immune microenvironment in non-small cell lung cancer patients with EGFR amplification and exploration of immunotherapy

Zhi Xian Jin, Min Chen, Xu He, Hong Bi, Chao Yang, Jing Shao, Zhaoming Huang, Yuyan Zhou, Cuilin Yang

Cancer Res (2025) 85 (8_Supplement_1): 4624.

https://doi.org/10.1158/1538-7445.AM2025-4624

Published: 21 April 2025

View articletitled, Abstract 4624: Analysis of the characteristics of immune microenvironment in non-small cell lung cancer patients with EGFR amplification and exploration of immunotherapy

Journal Articles

Abstract 1090: Multiomic analysis of Taiwanese NSCLC: insights from a predominantly non-smoking cohort

Hsu-Ching Huang, Samira Masoudi, Daniel Halmos, Chien-jung Huang, Yu-Chao Wang, Yi-Chen Yeh, Yung-Hung Luo, Han-Shui Hsu, Yuh-Min Chen, Chun-Ku Chen, Sandip Patel, Albert Hsiao

Cancer Res (2025) 85 (8_Supplement_1): 1090.

https://doi.org/10.1158/1538-7445.AM2025-1090

Published: 21 April 2025

View articletitled, Abstract 1090: Multiomic analysis of Taiwanese NSCLC: insights from a predominantly non-smoking cohort

Journal Articles

Abstract 383: Discovery of potent, selective, and orally bioavailable GSPT1 molecular glue degraders (MGDs) for the treatment of MYC-driven tumors

Zhimin Zhang, Min Chen, Cancan Cai, Li Teng, Sirui Liu, Yujie Chang, Xinxin Jin, Xiaohua Zhang, Dongzhou Liu

Cancer Res (2025) 85 (8_Supplement_1): 383.

https://doi.org/10.1158/1538-7445.AM2025-383

Published: 21 April 2025

View articletitled, Abstract 383: Discovery of potent, selective, and orally bioavailable GSPT1 molecular glue degraders (MGDs) for the treatment of MYC-driven tumors

Journal Articles

Abstract 142: Integrin α6β4 upregulates IDO1 expression and decreases IFNγ-mediated T cell growth in ER-negative breast cancer

Parvanee Karimpour, Oscar Hanson, Andrew Elliott, Min Chen, Kathleen O'Connor

Cancer Res (2025) 85 (8_Supplement_1): 142.

https://doi.org/10.1158/1538-7445.AM2025-142

Published: 21 April 2025

View articletitled, Abstract 142: Integrin α6β4 upregulates IDO1 expression and decreases IFNγ-mediated T cell growth in ER-negative breast cancer

Journal Articles

Abstract CT251: Savolitinib (savo) + osimertinib (osi) vs savo + placebo (PBO) in patients (pts) with EGFR-mutated (EGFRm), MET-amplified advanced NSCLC with progression on osi

James Chih-Hsin Yang, Yuh-Min Chen, Ullas Batra, Kien Do, Piyada Sitthideatphaiboon, Pongwut Danchaivijitr, Kang-Yun Lee, Jarin Chindaprasirt, Cheng-Ta Yang, Gee-Chen Chang, Chaiyut Charoentum, Teerapat Ungtrakul, Juan Ignacio Hernandez Moran, Ryan Hartmaier, Matthew Haskins, Wanning Xu, Jonathan W. Riess

Cancer Res (2024) 84 (7_Supplement): CT251.

https://doi.org/10.1158/1538-7445.AM2024-CT251

Published: 05 April 2024

View articletitled, Abstract CT251: Savolitinib (savo) + osimertinib (osi) vs savo + placebo (PBO) in patients (pts) with EGFR-mutated (EGFRm), MET-amplified advanced NSCLC with progression on osi

Journal Articles

Abstract 2526: Exploratory study of predicting systemic therapy response by IGRA in advanced stage NSCLC patients

Hsu Ching Huang, Chi-Lu Chiang, Yung-Hung Luo, Yuh-Min Chen, Chao-Hua Chiu

Cancer Res (2024) 84 (6_Supplement): 2526.

https://doi.org/10.1158/1538-7445.AM2024-2526

Published: 22 March 2024

View articletitled, Abstract 2526: Exploratory study of predicting systemic therapy response by IGRA in advanced stage NSCLC patients

Journal Articles

Abstract 6712: LBL-043, a novel LILRB4xCD3 T cell engager, for the treatment of LILRB4 positive leukemia

Yujia Dang, Xiao Huang, Yurong Qin, Xiaoya Liu, Min Chen, Duqing Jiang, Guojin Wu, Mi Ye, Jianming Sun, Baohui Wang, Jing Guan, Tingting Li, Jordan Zhu, Shoupeng Lai, Xiaoqiang Kang, Hong Ling

Cancer Res (2024) 84 (6_Supplement): 6712.

https://doi.org/10.1158/1538-7445.AM2024-6712

Published: 22 March 2024

View articletitled, Abstract 6712: LBL-043, a novel LILRB4xCD3 T cell engager, for the treatment of LILRB4 positive leukemia

Journal Articles

Abstract 437: Hydrogen sulfide switches the glucose metabolism through sulfhydration on pyruvate kinase M2

Cancer Res (2024) 84 (6_Supplement): 437.

https://doi.org/10.1158/1538-7445.AM2024-437

Published: 22 March 2024

View articletitled, Abstract 437: Hydrogen sulfide switches the glucose metabolism through sulfhydration on pyruvate kinase M2

Journal Articles

Abstract 7632: Final survival outcomes and post-hoc tumor gene expression pathway analyses of complete responders from a phase Ib clinical trial of HSP90 inhibitor onalespib and paclitaxel in patients with advanced triple-negative breast cancer

Cancer Res (2024) 84 (6_Supplement): 7632.

https://doi.org/10.1158/1538-7445.AM2024-7632

Published: 22 March 2024

View articletitled, Abstract 7632: Final survival outcomes and post-hoc tumor gene expression pathway analyses of complete responders from a phase Ib clinical trial of HSP90 inhibitor onalespib and paclitaxel in patients with advanced triple-negative breast cancer

Journal Articles

Abstract 6771: Tumor-microenvironment-on-chip: an ex vivo drug screening platform enabling real-time observation of regional tumor responses during drug development and clinical treatments

Chiao-Min Lin, Hsaun-Yu Mu, Li-An Chu, Ya-Hui Lin, Ji Li, Chao-Yu Liu, Hsi-Chien Huang, Sheng-Liang Cheng, Tsung-Ying Lee, Hsin Mei Lee, Hsin-Min Chen, Yun-Jen Tsai, Tzu-Hung Hsiao, Kee-Ming Man, Yunching Chen, Jen-Huang Huang

Cancer Res (2024) 84 (6_Supplement): 6771.

https://doi.org/10.1158/1538-7445.AM2024-6771

Published: 22 March 2024

View articletitled, Abstract 6771: Tumor-microenvironment-on-chip: an ex vivo drug screening platform enabling real-time observation of regional tumor responses during drug development and clinical treatments

Journal Articles

Abstract 2965: LBL-033, a novel bispecific antibody targeting MUC16 and CD3, for the treatment of tumors over-expressing MUC16

Jianming Sun, Xiao Huang, Yurong Qin, XingXing Fang, Min Chen, Huan Lin, Jing Guan, Jing Huang, Tongjun Liu, Baohui Wang, Guojin Wu, Shoupeng Lai, Xiaoqiang Kang, Hong Ling

Cancer Res (2023) 83 (7_Supplement): 2965.

https://doi.org/10.1158/1538-7445.AM2023-2965

Published: 04 April 2023

View articletitled, Abstract 2965: LBL-033, a novel bispecific antibody targeting MUC16 and CD3, for the treatment of tumors over-expressing MUC16

Journal Articles

Abstract CT572: Phase 1b dose-escalation and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd) in combination with durvalumab and cisplatin, carboplatin, or pemetrexed in advanced or metastatic, HER2-overexpressing, nonsquamous non-small cell lung cancer (NSCLC): DESTINY-Lung03

David Planchard, Julie R. Brahmer, James C. Yang, Yuh-Min Chen, Kang-Yun Lee, Thatthan Suksombooncharoen, Natasha Viglianti, Mark Gustavson, Alejandra Ragone, Amaya Gasco Hernandez

Cancer Res (2022) 82 (12_Supplement): CT572.

https://doi.org/10.1158/1538-7445.AM2022-CT572

Published: 15 June 2022

View articletitled, Abstract CT572: Phase 1b dose-escalation and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd) in combination with durvalumab and cisplatin, carboplatin, or pemetrexed in advanced or metastatic, HER2-overexpressing, nonsquamous non-small cell lung cancer (NSCLC): DESTINY-Lung03

Journal Articles

Abstract 3590: ZL-1218, a novel anti-CCR8 antibody, exerts potent antitumor effect by depleting intratumoral regulatory T cells

Jing Zhang, Wenhua Shi, Min Chen, Xinchuan Dai, Hongshui Liu, Shou Li, Lina Wang, Bee-Chun Sun, Monica You, Vivian Morton, Qiuping Ye, Lishan Kang, Bing Wan, Peter Brams, David I. Bellovin

Cancer Res (2022) 82 (12_Supplement): 3590.

https://doi.org/10.1158/1538-7445.AM2022-3590

Published: 15 June 2022

View articletitled, Abstract 3590: ZL-1218, a novel anti-CCR8 antibody, exerts potent antitumor effect by depleting intratumoral regulatory T cells

Journal Articles

Abstract CT504: A phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK) and efficacy of D-1553, a novel KRAS^G12C inhibitor, in patients with advanced or metastatic solid tumor harboring KRAS^G12C mutation

Timothy Price, Jaspreet Grewal, Afaf Abed, Melissa Moore, Yu-Min Yeh, Shirish Gadgeel, Gary Richardson, Craig Underhill, Vinod Ganju, Keun-Wook Lee, Seok Jae Huh, Sang-We Kim, Chih-Hsin Yang, Yuh-Min Chen, Ziyong Xiang, Zhe Shi, Yaolin Wang, Ling Zhang, Michael Millward

Cancer Res (2022) 82 (12_Supplement): CT504.

https://doi.org/10.1158/1538-7445.AM2022-CT504

Published: 15 June 2022

View articletitled, Abstract CT504: A phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK) and efficacy of D-1553, a novel KRASG12C inhibitor, in patients with advanced or metastatic solid tumor harboring KRASG12C mutation

Journal Articles

Abstract P3-06-04: Notch3 inhibits epithelia-mesenchymal transition by trans-activating GSK3β in breast cancer

Chen Wei-Ling, Yong-Qu Zhang, Wen-He Huang, Min Chen, Yao-Chen Li, Guo-Jun Zhang

Cancer Res (2022) 82 (4_Supplement): P3-06-04.

https://doi.org/10.1158/1538-7445.SABCS21-P3-06-04

Published: 15 February 2022

View articletitled, Abstract P3-06-04: Notch3 inhibits epithelia-mesenchymal transition by trans-activating GSK3β in breast cancer

Journal Articles

Abstract P3-02-10: Balixafortide-functionalized down-conversion NIR-IIb nanoparticles for lymph node-invaded breast cancer detection

Yuan-Yuan Zhu, Yong-Qu Zhang, Zun Wang, Min Chen, Guo-Jun Zhang

Cancer Res (2022) 82 (4_Supplement): P3-02-10.

https://doi.org/10.1158/1538-7445.SABCS21-P3-02-10

Published: 15 February 2022

View articletitled, Abstract P3-02-10: Balixafortide-functionalized down-conversion NIR-IIb nanoparticles for lymph node-invaded breast cancer detection

Journal Articles

Oncogenic circRNA C190 Promotes Non–Small Cell Lung Cancer via Modulation of the EGFR/ERK Pathway

Afeez Adekunle Ishola, Chian-Shiu Chien, Yi-Ping Yang, Yueh Chien, Aliaksandr A. Yarmishyn, Ping-Hsing Tsai, Jerry Chieh-Yu Chen, Po-Kuei Hsu, Yung-Hung Luo, Yuh-Min Chen, Kung-Hou Liang, Yuan-Tzu Lan, Teh-Ia Huo, Hsin-I. Ma, Ming-Teh Chen, Mong-Lien Wang, Shih-Hwa Chiou

Cancer Res (2022) 82 (1): 75–89.

https://doi.org/10.1158/0008-5472.CAN-21-1473

Published: 04 January 2022

View articletitled, Oncogenic circRNA C190 Promotes Non–Small Cell Lung Cancer via Modulation of the EGFR/ERK Pathway

Includes: Supplementary data

Journal Articles

Abstract 1203: ZL-1211 exhibits broad anti-tumor activity in CLDN18.2 high- and low-expressing models

Cancer Res (2021) 81 (13_Supplement): 1203.

https://doi.org/10.1158/1538-7445.AM2021-1203

Published: 01 July 2021

View articletitled, Abstract 1203: ZL-1211 exhibits broad anti-tumor activity in CLDN18.2 high- and low-expressing models

Update search

NARROW

Format

Subjects

Journal

Article Type

Issue Section

Date

Availability

Correction: SCF^FBXW7/GSK3β-Mediated GFI1 Degradation Suppresses Proliferation of Gastric Cancer Cells

Abstract 7323: LBL-043, a novel LILRB4xCD3 T cell engager, for the treatment of relapsed/refractory multiple myeloma

Abstract 4624: Analysis of the characteristics of immune microenvironment in non-small cell lung cancer patients with EGFR amplification and exploration of immunotherapy

Abstract 1090: Multiomic analysis of Taiwanese NSCLC: insights from a predominantly non-smoking cohort

Abstract 383: Discovery of potent, selective, and orally bioavailable GSPT1 molecular glue degraders (MGDs) for the treatment of MYC-driven tumors

Abstract 142: Integrin α6β4 upregulates IDO1 expression and decreases IFNγ-mediated T cell growth in ER-negative breast cancer

Abstract CT251: Savolitinib (savo) + osimertinib (osi) vs savo + placebo (PBO) in patients (pts) with EGFR-mutated (EGFRm), MET-amplified advanced NSCLC with progression on osi

Abstract 2526: Exploratory study of predicting systemic therapy response by IGRA in advanced stage NSCLC patients

Abstract 6712: LBL-043, a novel LILRB4xCD3 T cell engager, for the treatment of LILRB4 positive leukemia

Abstract 437: Hydrogen sulfide switches the glucose metabolism through sulfhydration on pyruvate kinase M2

Abstract 7632: Final survival outcomes and post-hoc tumor gene expression pathway analyses of complete responders from a phase Ib clinical trial of HSP90 inhibitor onalespib and paclitaxel in patients with advanced triple-negative breast cancer

Abstract 6771: Tumor-microenvironment-on-chip: an ex vivo drug screening platform enabling real-time observation of regional tumor responses during drug development and clinical treatments

Abstract 2965: LBL-033, a novel bispecific antibody targeting MUC16 and CD3, for the treatment of tumors over-expressing MUC16

Abstract CT572: Phase 1b dose-escalation and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd) in combination with durvalumab and cisplatin, carboplatin, or pemetrexed in advanced or metastatic, HER2-overexpressing, nonsquamous non-small cell lung cancer (NSCLC): DESTINY-Lung03

Abstract 3590: ZL-1218, a novel anti-CCR8 antibody, exerts potent antitumor effect by depleting intratumoral regulatory T cells

Abstract CT504: A phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK) and efficacy of D-1553, a novel KRAS^G12C inhibitor, in patients with advanced or metastatic solid tumor harboring KRAS^G12C mutation

Abstract P3-06-04: Notch3 inhibits epithelia-mesenchymal transition by trans-activating GSK3β in breast cancer

Abstract P3-02-10: Balixafortide-functionalized down-conversion NIR-IIb nanoparticles for lymph node-invaded breast cancer detection

Oncogenic circRNA C190 Promotes Non–Small Cell Lung Cancer via Modulation of the EGFR/ERK Pathway

Abstract 1203: ZL-1211 exhibits broad anti-tumor activity in CLDN18.2 high- and low-expressing models

Email alerts

AACR Journals

Update search

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only